Ovid Therapeutics Inc.
OVID
$0.3383
-$0.0117-3.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 76.00K | 173.00K | 169.00K | 148.00K | 142.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.00K | 173.00K | 169.00K | 148.00K | 142.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 76.00K | 173.00K | 169.00K | 148.00K | 142.00K |
| SG&A Expenses | 6.78M | 5.54M | 6.30M | 7.17M | 6.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.00M | 13.40M | 18.89M | 17.57M | 16.63M |
| Operating Income | -10.92M | -13.23M | -18.72M | -17.42M | -16.49M |
| Income Before Tax | -9.25M | -14.01M | 8.52M | -11.69M | -15.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.25M | -14.01M | 8.52M | -11.69M | -15.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.25M | -14.01M | 8.52M | -11.69M | -15.32M |
| EBIT | -10.92M | -13.23M | -18.72M | -17.42M | -16.49M |
| EBITDA | -10.76M | -13.06M | -18.57M | -17.28M | -16.35M |
| EPS Basic | -0.12 | -0.20 | 0.12 | -0.17 | -0.20 |
| Normalized Basic EPS | -0.08 | -0.12 | 0.09 | -0.11 | -0.13 |
| EPS Diluted | -0.13 | -0.20 | 0.12 | -0.17 | -0.21 |
| Normalized Diluted EPS | -0.08 | -0.12 | 0.09 | -0.11 | -0.13 |
| Average Basic Shares Outstanding | 71.01M | 70.98M | 70.92M | 70.72M | 70.69M |
| Average Diluted Shares Outstanding | 71.01M | 70.98M | 71.20M | 70.72M | 70.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |